Top Tweets for #Brepocitinib
π#FDA Approval Update | The approval of #brepocitinib brings a targeted #TYK2/#JAK1 approach to a disease with significant unmet treatment needs.
#FDA #AutoimmuneDisease #Inflammation #DrugDevelopment
π¨#FDA Approval Update | A new treatment option for #Dermatomyositis
The FDA has approved #Lisraya (#brepocitinib) as the first FDA-approved oral treatment for adults with dermatomyositis, a rare #autoimmune disease where the immune system attacks muscles and skin.
πAs a #TYK2/#JAK1 inhibitor, brepocitinib targets key signaling pathways involved in inflammation.
π¬The approval addresses a major unmet need for patients who have long relied on therapies not specifically for dermatomyositis.
Read more: https://t.co/HOKSXc4HEf
#FDAApproval #AutoimmuneDisease #Inflammation #ChronicInflammation #DrugDevelopment
π¨#FDA Approval Update | A new treatment option for #Dermatomyositis
The FDA has approved #Lisraya (#brepocitinib) as the first FDA-approved oral treatment for adults with dermatomyositis, a rare #autoimmune disease where the immune system attacks muscles and skin.
πAs a #TYK2/#JAK1 inhibitor, brepocitinib targets key signaling pathways involved in inflammation.
π¬The approval addresses a major unmet need for patients who have long relied on therapies not specifically for dermatomyositis.
Read more: https://t.co/HOKSXc4HEf
#FDAApproval #AutoimmuneDisease #Inflammation #ChronicInflammation #DrugDevelopment
FDAβs approval of #Lisraya (#brepocitinib) marks the first oral therapy for dermatomyositis and first approval for a dual TYK2/JAK #inhibitor. This adds to the clinical validation for these inhibitors as we advance SDC-1801 through clinical development.
https://t.co/ClylatacYz
π¨ #Brepocitinib has been approved by the FDA, marking the first oral treatment specifically indicated for adult #dermatomyositis. Phase 3 data showed significant improvements in disease activity, skin symptoms, and steroid-sparing outcomes.
https://t.co/cAh03qAm2j #DermTwitter
π Phase 3 RCT of #Brepocitinib (TYK2-JAK1 inhibitor) vs PBO in #Dermatomyositis (The VALOR Trial) π₯
β Rapid onset: improvements as early as wk 4
πͺ All pts had both active muscle + skin disease
π Improvement in myositis activity, GC tapering
#Myositis #Rheumatology #DermX
5 top abstracts in #Myositis @eular_org
1 #Nailfold #capillaries as an early marker of #IIM Rx
2 #brepocitinib +RCT #DM
3 & rapid skin improvement #CLASI
4 #Ab may help #IBM but neg primary endpoint
5 #criteria for #antisynthetase
#EULAR2026 @RheumNow
OP0168, 0166, 0164 POS264
+#RCT in #dermatomyositis with #brepocitinib
Oral #TYK2/JAK1i
241 pts
+outcomes
#TIS total improvement score
>40%TIS 68% v 44%
#steroid tapering
#skin improved rapidly #CLASI
#OP0166
#POS0264 @RheumNow #EULAR2026
π‘ Oral JAK inhibitor #brepocitinib shows promise in phase 2/3 trials for lichen planopilaris. It may become the first FDA-approved systemic option, improving access and outcomes.
https://t.co/PdhQux3Xrl #LPP #LichenPlanopilaris #ScarringAlopecia #DermTwitter
β#Brepocitinib has entered a phase 2b/3 trial for #LichenPlanopilaris, a scarring #alopecia with no approved treatments. The TYK2/JAK1 inhibitor could address a major unmet need and become the first FDA-approved therapy for #LPP.
https://t.co/9EE2FFFlZ2 #DermTwitter
β°οΈ CONFERENCE HIGHLIGHTS: New data published in the New England Journal of Medicine and presented at #AAD2026 detailed phase 3 VALOR results of #brepocitinib for dermatomyositis.
Read more: https://t.co/kRjET2fG2o
π Phase 2 BEACON data shows #brepocitinib delivered rapid, significant clearance in cutaneous sarcoidosis, with early separation from placebo, high remission rates, and good tolerability.
https://t.co/6ahoGc73pR #DermTwitter #CS
Research Article by BB Nayak et al. (@rishi7rajesh @MedUniGraz @LUMC_Leiden) #Brepocitinib, a selective TYK2/JAK1 inhibitor, mitigates #neutrophilic #inflammation and #glucocorticoid receptor-Ξ² expression in #COPD
https://t.co/Jp3Puyqlnl
First-In-Class Therapies For Severe Autoimmune Disorders - Benjamin Zimmer - CEO, #PriovantTherapeutics joins me on Progress, Potential, And Possibilities #AutoimmuneDiseases #Brepocitinib #TYK2 #JAK1 #Dermatomyositis #NonInfectiousUveitis
First-In-Class Therapies For Severe Autoimmune Disorders - Ben Zimmer - CEO, Priovant Therapeutics @Roivant @priovanttx @ProgressPotent1 @irat1onal
@pfizer @VivekGRamaswamy @russopartners
#AutoimmuneDiseases #Brepocitinib #TYK2 #JAK1 #Dermatomyositis #NonInfectiousUveitis https://t.co/OiCwcCjrm3
Ph 2a 16-wk Hidradenitis Suppurativa study (3) $PFE $ROIV drugs:
πΉ#brepocitinib #JAK1/#TYK2 inhibitor
πΉ#zimlovisertib #IRAK4 inhibitor
πΉ#ropsacitinib #TYK2 inhibitor
Conclusion:
Results favor JAK/STAT pathway in HS, but did NOT confirm a role for selective IRAK4 or TYK2 inhibition as they were no different than placebo.
https://t.co/YjKg20RiDK
Implications for $KYMR IRAK4 degrader program in HS. Kymera and partner $SNY in June no longer advancing lead compound KT-474 in HS despite being in middle of Ph 2b trial, replacing w/ back-up KT-0485‡οΈ
https://t.co/ApzDXytiGL
https://t.co/yd6fImEO7V
Note: zimlovisertib is an IRAK4 inhibitor and affects only the kinase activity of the enzyme, whereas $KYMR IRAK4 degrader will affect BOTH the kinase and scaffolding functions of the enzyme so may see different result?
Novel Therapies For Severe Autoimmune Diseases - Ben Zimmer - CEO, Priovant Therapeutics @priovanttx @ProgressPotent1 @Roivant @pfizer @VivekGRamaswamy
#BenZimmer #PriovantTherapeutics #AutoimmuneDiseases #Brepocitinib #TYK2 #JAK1 #Dermatomyositis #NonInfectiousUveitis #Pfizer #Roivant #VivekRamaswamy #ProgressPotentialAndPossibilities #IraPastor #Podcast #STEM #Innovation #Technology #Science #Research https://t.co/mQK6kfrzEQ
#Brepocitinib, in doses of either 30 mg or 60 mg, is superior to placebo in reducing signs and symptoms of psoriatic #arthritis and is βgenerally well toleratedβ through 52 weeks
https://t.co/xG5vcyllSt
In a recent study, TYK2/JAK1 inhibitor #brepocitinib was significantly more efficacious in reducing signs and symptoms of #PsoriaticArthritis than a placebo.
https://t.co/HpwEdZZMpB
#Ritlecitinib, #brepocitinib outperform placebo for treatment of moderate to severe #UC @AGA_CGH @HealioGastro https://t.co/GAOT4CF2Yw
#Brepocitinib proved to be effective and well tolerated as a formation in patients with mild to moderate atopic dermatitis, according to a phase 2b study. https://t.co/AheLnmhl6g
Last Seen Hashtags on Sotwe
backwards
Tychella
Seen from Colombia
ζ΅εΊ
Seen from United States
incestoreal
Seen from Argentina
ΰΈΰΈ±ΰΈΰΈ₯ΰΈΈΰΈ
Seen from Thailand
unexpected
Seen from United Kingdom
RBMS
Seen from Korea
creepshot ()()()()
Seen from Germany
minichat((((*))))* filter:videos
Seen from Italy
Unexpected
Seen from Australia
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers